

Supplementary Materials:

| Bacterium                                      | Cultivation medium                                                | Cultivation condition |
|------------------------------------------------|-------------------------------------------------------------------|-----------------------|
| <i>Lactobacillus plantarum</i> CCDM 182        | MRS Broth for Lactobacilli (ATCC Medium No. 416)                  | anaerobic             |
| <i>Bifidobacterium adolescentis</i> CCUG 18363 | DSMZ medium No. 58. for Bifidobacteria                            | anaerobic             |
| <i>Blautia coccoides</i>                       | Modified chopped meat medium (ATCC Medium No. 1490)               | anaerobic             |
| <i>Roseburia intestinalis</i> L1-82            | Keister's Modified TYI-S-33 (ATCC Medium No. 2695)                | anaerobic             |
| <i>Eubacterium rectale</i> ATCC 33656          | Chopped meat carbohydrates with rumen fluid (ATCC Medium No 1703) | anaerobic             |
| <i>Faecalibacterium prausnitzii</i> A2-165     | Modified YCFA medium (DSMZ medium No. 1611)                       | anaerobic             |
| <i>Ruminococcus flavefaciens</i> DSM 25089     | Medium for anerobes with 0.1% cellobiose (ATCC Medium No. 1365 E) | anaerobic             |
| <i>Bacteroides thetaiotaomicron</i> VPI 5482   | Modified chopped meat medium (ATCC Medium No. 1490)               | anaerobic             |
| <i>Prevotella ruminicola</i> M384              | Chopped meat carbohydrates with rumen fluid (ATCC Medium No 1703) | anaerobic             |
| <i>Escherichia coli</i> K6                     | Luria-Bertani broth (Merck, L3022)                                | aerobic               |

Table S1: Bacteria and cultivation conditions




Figure S1: Significant differences in serum biomarkers between PSC-IBD, UC and CD patients and healthy controls as analyzed by Kruskal-Wallis test with Dunn's multiple comparison test. Different letters indicate statistical significant differences.




Figure S2: Serum biomarkers do not describe the extent of colitis well. (A) Heat map and cluster analysis of the chosen proteins. (B) Composite ROC curve analysis for the biomarkers discriminating between partial and total colonic inflammation using the best model found by regression analysis. PSC-IBD (n=29), UC (n=34), CD (n=19).




Figure S3: Only few serum biomarkers are influenced by IBD treatment, but their discriminating power is generally low. (A) Heat map and cluster analysis of the serum biomarkers. (B) Relative importance of each cytokine for the AUC increment within the best model found by regression analysis and quantitative plot of the strongest discriminating factor analyzed by Mann Whitney test. \* p<0.05, \*\* p<0.01; other = anti-α4β7 PSC-IBD (n=31), UC (n=34), CD (n=20).




Figure S4: Serum antimicrobial antibodies are influenced by IBD treatment only to a limited degree. (A) Heatmap and cluster analysis of the serum biomarkers. (B) Relative importance of each anti-microbial antibody for the AUC increment within the best model found by regression analysis and quantitative plot of the strongest discriminating factor analyzed by Mann Whitney test. \*  $p < 0.05$ ; other = anti- $\alpha 4\beta 7$ ; PSC-IBD (n=32), UC (n=37), CD (n=20).




Figure S5: Anti-TNF- $\alpha$  treatment influences cellular antimicrobial response in IBD patients. (A) Heat map and cluster analysis of the serum biomarkers. (B) Quantitative plot of the strongest discriminating factors selected by correlation analysis as analyzed by Mann Whitney test. \*\*\*  $p < 0.001$ . PSC-IBD (n=8), UC (n=14), CD (n=17), AZA treated (n=13), AZA non-treated (n=26), anti-TNF- $\alpha$  treated (n=10), anti-TNF- $\alpha$  non-treated (n=27)




Figure S6: Response of memory T helper cells has a specific profile for each healthy controls (n=14) and PSC-IBD (n=9), UC (n=12) and CD (n=13) patients as analyzed by non-parametric paired Friedman test with Dunn's multiple comparison test. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001




Figure S7: Gating strategy for flow cytometry using SEB-stimulated PBMCs